The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.
“Liquid biopsy” analyses of circulating tumor DNA from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer, and might point the way for development of new targeted treatments.
A long-term study found that adding 24 months of antiandrogen therapy with bicalutamide to salvage radiation therapy increased overall survival and prostate cancer–specific survival compared with placebo in men who underwent radical prostatectomy.
The use of multi-parametric magnetic resonance imaging could allow more than a quarter of men with high prostate-specific antigen levels to avoid undergoing transrectal ultrasound-guided prostate biopsy.
Active surveillance is an excellent alternative to surgery or radiation in patients with low-risk cancers. However, the current methods of ascertaining whether a patient harbors a low-risk cancer are flawed.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.